GOSS

Gossamer Bio, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$11.24

Price (1 Year)

$288 $8.77

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %13.2 / %30
Non-compliant assets / Total market cap %5.8 / %30
Non-compliant revenue / Total income %62.9 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Website

Analysis (Turkish): GOSS Hissesi Caiz mi, Helal mi? Gossamer Bio, Inc. Katılım Analizi